252 related articles for article (PubMed ID: 32972603)
1. RASopathies.
Jafry M; Sidbury R
Clin Dermatol; 2020; 38(4):455-461. PubMed ID: 32972603
[TBL] [Abstract][Full Text] [Related]
2. Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
Gross AM; Frone M; Gripp KW; Gelb BD; Schoyer L; Schill L; Stronach B; Biesecker LG; Esposito D; Hernandez ER; Legius E; Loh ML; Martin S; Morrison DK; Rauen KA; Wolters PL; Zand D; McCormick F; Savage SA; Stewart DR; Widemann BC; Yohe ME
Am J Med Genet A; 2020 Apr; 182(4):866-876. PubMed ID: 31913576
[TBL] [Abstract][Full Text] [Related]
3. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.
Zenker M
Curr Opin Pediatr; 2011 Aug; 23(4):443-51. PubMed ID: 21750428
[TBL] [Abstract][Full Text] [Related]
4. Dermatological manifestations, management, and care in RASopathies.
Kavamura MI; Leoni C; Neri G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):452-458. PubMed ID: 36541891
[TBL] [Abstract][Full Text] [Related]
5. The RASopathies: from pathogenetics to therapeutics.
Hebron KE; Hernandez ER; Yohe ME
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35178568
[TBL] [Abstract][Full Text] [Related]
6. Oculoectodermal Syndrome - Encephalocraniocutaneous Lipomatosis Associated with NRAS Mutation.
Richters RJH; Seyger MMB; Meeuwis KAP; Rinne T; Eijkelenboom A; Willemsen MA
Acta Derm Venereol; 2020 Apr; 100(8):adv00103. PubMed ID: 31633190
[No Abstract] [Full Text] [Related]
7. Next generation sequencing aids diagnosis and management in a case of encephalocraniocutaneous lipomatosis.
Barry KK; Liang MG; Balkin DM; Srivastava S; Church AJ; Eng W
Pediatr Dermatol; 2024; 41(1):76-79. PubMed ID: 37486073
[TBL] [Abstract][Full Text] [Related]
8. Encephalocraniocutaneous Lipomatosis.
Bavle A; Shah R; Gross N; Gavula T; Ruiz-Elizalde A; Wierenga K; McNall-Knapp R
J Pediatr Hematol Oncol; 2018 Oct; 40(7):553-554. PubMed ID: 29683947
[TBL] [Abstract][Full Text] [Related]
9. Mosaic KRAS mutation in a patient with encephalocraniocutaneous lipomatosis and renovascular hypertension.
McDonell LM; Leung GK; Daoud H; Ip J; Chim S; Luk HM; Lan L; ; Boycott KM; Chung BH
Am J Med Genet A; 2018 Nov; 176(11):2523-2527. PubMed ID: 30289595
[No Abstract] [Full Text] [Related]
10. A review of craniofacial and dental findings of the RASopathies.
Cao H; Alrejaye N; Klein OD; Goodwin AF; Oberoi S
Orthod Craniofac Res; 2017 Jun; 20 Suppl 1(Suppl 1):32-38. PubMed ID: 28643916
[TBL] [Abstract][Full Text] [Related]
11. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
[TBL] [Abstract][Full Text] [Related]
12. Malignancy in Noonan syndrome and related disorders.
Smpokou P; Zand DJ; Rosenbaum KN; Summar ML
Clin Genet; 2015 Dec; 88(6):516-22. PubMed ID: 25683281
[TBL] [Abstract][Full Text] [Related]
13. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
Bezniakow N; Gos M; Obersztyn E
Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in RASopathies.
Aoki Y; Niihori T; Inoue S; Matsubara Y
J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
[TBL] [Abstract][Full Text] [Related]
15. Peripheral muscle weakness in RASopathies.
Stevenson DA; Allen S; Tidyman WE; Carey JC; Viskochil DH; Stevens A; Hanson H; Sheng X; Thompson BA; Okumura MJ; Reinker K; Johnson B; Rauen KA
Muscle Nerve; 2012 Sep; 46(3):394-9. PubMed ID: 22907230
[TBL] [Abstract][Full Text] [Related]
16. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.
Gripp KW; Lin AE
Genet Med; 2012 Mar; 14(3):285-92. PubMed ID: 22261753
[TBL] [Abstract][Full Text] [Related]
17. Expansion of the phenotypic spectrum and description of molecular findings in a cohort of patients with oculocutaneous mosaic RASopathies.
Chacon-Camacho OF; Lopez-Moreno D; Morales-Sanchez MA; Hofmann E; Pacheco-Quito M; Wieland I; Cortes-Gonzalez V; Villanueva-Mendoza C; Zenker M; Zenteno JC
Mol Genet Genomic Med; 2019 May; 7(5):e625. PubMed ID: 30891959
[TBL] [Abstract][Full Text] [Related]
18. [New insight of craniofacial and oral findings of the RASopathies].
Cao HT; Yang YJ; Zheng Q; Shi B; Li CH
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Dec; 53(12):858-861. PubMed ID: 30522213
[TBL] [Abstract][Full Text] [Related]
19. Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.
Leung GKC; Luk HM; Tang VHM; Gao WW; Mak CCY; Yu MHC; Wong WL; Chu YWY; Yang WL; Wong WHS; Ma ACH; Leung AYH; Jin DY; Chan KYK; Allanson J; Lo IFM; Chung BHY
Sci Rep; 2018 Feb; 8(1):2421. PubMed ID: 29402968
[TBL] [Abstract][Full Text] [Related]
20. New prospectives on treatment opportunities in RASopathies.
Gelb BD; Yohe ME; Wolf C; Andelfinger G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):541-560. PubMed ID: 36533679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
